Literature DB >> 9057650

Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization.

P Mathew1, W G Sanger, D D Weisenburger, M Valentine, V Valentine, D Pickering, C Higgins, M Hess, X Cui, D K Srivastava, S W Morris.   

Abstract

The non-Hodgkin's lymphoma (NHL) subset commonly referred to as large cell lymphoma (LCL) has historically been characterized by it's marked cytological, immunological, and clinical heterogeneity. One potential defining feature of these lymphomas, the t(2;5)(p23;q35), occurs in 25% to 30% of anaplastic LCLs and is also found in cases with diffuse large cell or immunoblastic morphology. We recently identified nucleophosmin (NPM) and anaplastic lymphoma kinase (ALK) as the genes on chromosomes 5 and 2, respectively, that are juxtaposed by this translocation. To provide a complementary approach to the use of classical cytogenetics or polymerase chain reaction-based methods for the detection of this abnormality, we have developed a two-color fluorescent in situ hybridization (FISH) assay for the t(2;5) that may be used for the analysis of both interphase nuclei and metaphase chromosomes. Three overlapping chromosome 5 cosmid clones located immediately centromeric to the NPM gene locus and an ALK P1 clone located telomeric to the chromosome 2 breakpoint were labeled with digoxigenin or biotin, respectively, and used to visualize the derivative chromosome 5 produced by the t(2;5), evident as juxtaposed or overlapping red and green fluorescent signals. This NPM-ALK FISH assay was initially validated by analysis of a series of cytogenetically characterized cell lines, with the presence of the der(5) chromosome showed specifically only in those lines known to contain the t(2;5). The assay was then applied in a blinded fashion to a series of eight cytogenetically t(2;5)-positive clinical specimens and seven known t(2;5)-negative cases, including three NHL and four Hodgkin's disease biopsy samples. Whereas the t(2;5)-negative cases were negative by FISH, all eight t(2;5)-positive cases were positive. One additional case, initially thought to be positive for the translocation by cytogenetics, was proven to not be a classic t(2;5) by interphase and metaphase FISH. These data indicate that the FISH assay described is a highly specific and rapid test that should prove to be a useful adjunct to the currently available methods for detection of the t(2;5).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9057650

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.

Authors:  B Maes; V Vanhentenrijk; I Wlodarska; J Cools; B Peeters; P Marynen; C de Wolf-Peeters
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.

Authors:  S Pittaluga; I Wlodarska; K Pulford; E Campo; S W Morris; H Van den Berghe; C De Wolf-Peeters
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

3.  The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.

Authors:  Samar A Hegazy; Peng Wang; Mona Anand; Robert J Ingham; Pascal Gelebart; Raymond Lai
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

4.  Complex genomic rearrangement of ALK loci associated with integrated human Epstein-Barr virus in a post-transplant myogenic liver tumor.

Authors:  Maria Debiec-Rychter; Romaric Croes; Rita De Vos; Peter Marynen; Tania Roskams; Anne Hagemeijer; Rita Lombaerts; Raf Sciot
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

5.  Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma.

Authors:  L Korashy; H El-Zawahry; S Abdou; D Shahin; F Sherif; W Farrag; O Abdel-Khalik; H Salem; A El-Sebaaie
Journal:  Clin Med Insights Oncol       Date:  2012-11-26

6.  SEC31A-ALK Fusion Gene in Lung Adenocarcinoma.

Authors:  Ryong Nam Kim; Yoon-La Choi; Mi-Sook Lee; Maruja E Lira; Mao Mao; Derrick Mann; Joshua Stahl; Abel Licon; So Jung Choi; Michael Van Vrancken; Joungho Han; Iwona Wlodarska; Jhingook Kim
Journal:  Cancer Res Treat       Date:  2015-02-17       Impact factor: 4.679

7.  Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.

Authors:  Jo-Anne van der Krogt; Marlies Vanden Bempt; Julio Finalet Ferreiro; Nicole Mentens; Kris Jacobs; Ursula Pluys; Kathleen Doms; Ellen Geerdens; Anne Uyttebroeck; Pascal Pierre; Lucienne Michaux; Timothy Devos; Peter Vandenberghe; Thomas Tousseyn; Jan Cools; Iwona Wlodarska
Journal:  Haematologica       Date:  2017-06-28       Impact factor: 9.941

Review 8.  ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.

Authors:  Mingxiang Ye; Xinxin Zhang; Nan Li; Yong Zhang; Pengyu Jing; Ning Chang; Jianxiong Wu; Xinling Ren; Jian Zhang
Journal:  Oncotarget       Date:  2016-03-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.